14M124: Is Fibromyalgia an Autoimmune Disease? An Update on Pathogenesis

Monday, November 14, 2022

10:30 AM – 11:30 AM Eastern Time

Location: Room 126

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

AG

Andreas Goebel, MD

University of Liverpool
Liverpool, United Kingdom

Disclosure(s): No financial relationships with ineligible companies to disclose

This session will provide attendees with an understanding of immune system contribution to neuroinflammation. These talks will illustrate how a deeper understanding of the pathogenesis of neuroinflammation can lead to the development of future therapeutics for fibromyalgia and pain associated with autoimmune disorders.

Learning Objectives:

Review the clinical implications of recent scientific discoveries regarding neuroinflammation
Explore how nociceptor signaling can lead to inflammatory responses
Describe the potential benefits of immune-based therapies for pain management in patients with chronic inflammatory diseases

Presentations:

10:30 AM – 10:45 AM Eastern Time

Neuronal IL-1 Receptors Mediate Pain in Chronic Inflammatory Diseases
Speaker: Steve Lacroix, PhD – Université Laval
10:45 AM – 10:50 AM Eastern Time

Q&A
10:50 AM – 11:05 AM Eastern Time

Introduction and Commentary
Speaker: Andrew Schrepf, PhD – University of Michigan
11:05 AM – 11:10 AM Eastern Time

Q&A
11:10 AM – 11:25 AM Eastern Time

HMGB1 Released from Nociceptors Mediates Inflammation
Speaker: Sangeeta Chavan, PhD – Feinstein Institutes for Medical Research, Northwell Health
11:25 AM – 11:30 AM Eastern Time

Q&A